GH Research PLC (GHRS)
| Market Cap | 1.31B +40.9% |
| Revenue (ttm) | n/a |
| Net Income | -62.27M |
| EPS | -0.99 |
| Shares Out | 68.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 560,158 |
| Open | 18.84 |
| Previous Close | 18.49 |
| Day's Range | 18.00 - 19.81 |
| 52-Week Range | 12.04 - 31.44 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 42.89 (+124.56%) |
| Earnings Date | Nov 13, 2026 |
About GHRS
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for GHRS stock is "Strong Buy." The 12-month stock price target is $42.89, which is an increase of 124.56% from the latest price.
News
GH Research reports Q3 EPS (18c), consensus (30c)
“Women with postpartum depression need treatments that work quickly and ask little of them at a time when they are caring for a newborn. In the Phase 2a trial, every…
GH Research appoints Vanina Popova as chief development officer
GH Research (GHRS) announced the appointment of Vanina Popova as chief development officer, to lead the clinical development of GH001 into our pivotal programs in treatment-resistant depression and po...
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support going from 3 → 1 doses per treatment visit TRD pivotal program — positive initial feedback from FDA, E...
GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
DUBLIN, Nov. 13, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t...
GH Research price target raised to $40 from $35 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on GH Research (GHRS) to $40 from $35 and keeps an Overweight rating on the shares.
GH Research price target raised to $40 from $34 at Guggenheim
Guggenheim analyst Eddie Hickman raised the firm’s price target on GH Research (GHRS) to $40 from $34 and keeps a Buy rating on the shares.
GH Research price target raised to $39 from $32 at Needham
Needham analyst Ami Fadia raised the firm’s price target on GH Research (GHRS) to $39 from $32 and keeps a Buy rating on the shares. The “main update” from the…
Psychedelic: Compass Pathways, GH Research report quarterly earnings
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a DSMB approval and a CEO appointment. EARNINGS: On Thursday, GH…
GH Research Slides: Corporate presentation
GH Research has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
GH Research reports Q2 EPS (23c), consensus (30c)
The company said, “We have completed GH001-HV-106, our Phase 1 clinical pharmacology trial of our proprietary aerosol delivery device in healthy volunteers, and GH001-HV-109, our IND-opening Phase 1 t...
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
Alignment with FDA on CMC and device plans for Phase 3 Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estate Phase 2a result...
GH Research Earnings release: Q2 2026
GH Research released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
GH Research initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of GH Research (GHRS) with an Overweight rating and $44 price target The firm says the stock’s current valuation implies skepticism that the company’s Phase 2b…
GH Research announces publication of Phase 2a results for mebufotenin
GH Research (GHRS) announced the publication of the full results from its Phase 2a trial in postpartum depression and the acceptance of two oral presentations at the 37th World Congress…
GH Research Announces Publication of Phase 2a Postpartum Depression Results
DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance o...
GH Research Earnings release: Q1 2026
GH Research released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
GH Research Registration statement: Registration filing
GH Research filed a registration statement on May 14, 2026, providing details about a securities offering with the SEC.
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enr...
GH Research Slides: Corporate presentation
GH Research has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
GH Research Announces Pricing of $117.5 Million Underwritten Offering
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing ...
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research
The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has b...
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing ...
Psychedelic stocks rally with Trump's support
An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.